Jason Infeld, MD
Cardiovascular Disease · Memphis, TNNPI 1194827089
Payments from drug & device makers
Across 337 payments — averaging $18.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Amgen$864
- Merck$486
- Actelion Pharmaceuticals US, Inc.$449
- Novo Nordisk$437
- E.r. Squibb & Sons, L.L.C.$412
- plus $2K from 24 others
What the payments were for
- Food & beverage$6,134100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 110 | $1,009 |
| Amgen | 32 | $864 |
| Merck | 28 | $486 |
| Actelion Pharmaceuticals US, Inc. | 20 | $449 |
| Novo Nordisk | 15 | $437 |
| E.r. Squibb & Sons, L.L.C. | 20 | $412 |
| Pfizer | 15 | $319 |
| Abbott | 3 | $246 |
| Johnson & Johnson | 15 | $239 |
| Medtronic | 2 | $237 |
| Boehringer Ingelheim | 10 | $196 |
| Philips North America LLC | 10 | $188 |
| AstraZeneca | 11 | $181 |
| Bridgebio Pharma, Inc. | 7 | $178 |
| Alnylam Pharmaceuticals Inc. | 6 | $133 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $107 |
| Bayer | 5 | $87 |
| Esperion Therapeutics, Inc. | 4 | $72 |
| Baxter Healthcare | 4 | $71 |
| Boston Scientific | 2 | $39 |
| Scpharmaceuticals Inc. | 1 | $27 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Daxor Corporation | 1 | $23 |
| Inspire Medical Systems, Inc. | 1 | $21 |
| Vifor Pharma, Inc. | 1 | $21 |
| Lilly USA, LLC | 1 | $18 |
| Lexicon Pharmaceuticals, Inc. | 1 | $16 |
| Biotronik Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$265
- MitraClip$162
- COREVALVE EVOLUT R$140
- Ozempic$119
- VYNDAQEL$102
How this compares
$6,142 in reported general payments places this provider in the 65th percentile of 429 cardiovascular disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 344 | $344,724 |
| UptraviSelexipag | 11 | $238,272 |
| XareltoRivaroxaban | 160 | $176,563 |
| EntrestoSacubitril/Valsartan | 133 | $152,913 |
| OpsumitMacitentan | 12 | $141,946 |
| JardianceEmpagliflozin | 60 | $68,945 |
| Repatha SureclickEvolocumab | 50 | $44,161 |
| FarxigaDapagliflozin Propanediol | 32 | $37,487 |
| MounjaroTirzepatide | 19 | $27,322 |
| Praluent PenAlirocumab | 29 | $26,756 |
| OzempicSemaglutide | 21 | $21,164 |
| BrilintaTicagrelor | 17 | $18,197 |
| Ezetimibe | 365 | $9,315 |
| NexlizetBempedoic Acid/Ezetimibe | 21 | $9,189 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 26 | $7,181 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $449 | $380,21923 claims |
| PfizerEliquis | $319 | $344,724344 claims |
| Johnson & JohnsonXarelto | $239 | $176,563160 claims |
| NovartisEntresto | $1,009 | $152,913133 claims |
| Boehringer IngelheimJardiance | $196 | $68,94560 claims |
| AstraZenecaFarxiga, Brilinta | $181 | $55,68549 claims |
| Lilly USA, LLCMounjaro | $18 | $27,32219 claims |
| Novo NordiskOzempic | $437 | $21,16421 claims |
| Esperion Therapeutics, Inc.Nexlizet | $72 | $9,18921 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 429 cardiovascular disease providers in Tennessee.
Other cardiovascular disease in Memphis
- Frank McGrewMemphis$2.1M
- Steven GubinMemphis$248K
- Kodangudi RamanathanMemphis$203K
- Adedayo AdeboyeMemphis$129K
- Kishore ArcotMemphis$124K
- Isaac RheaMemphis$75K
- Brian LindmanNashville$5.5M
- David MetzgerKingsport$4.8M
- Christopher EllisNashville$4.1M
- Dinesh GuptaNashville$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.